Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
ZyVersa Therapeutics Inc (Nasdaq: ZVSA) is a clinical-stage biopharmaceutical company pioneering treatments for renal and inflammatory diseases through its Cholesterol Efflux Mediator and Inflammasome ASC Inhibitor platforms. This dedicated news hub provides investors and medical professionals with timely updates on clinical developments, regulatory milestones, and scientific advancements.
Access verified press releases and curated news about ZVSA's innovative pipeline, including progress on VAR 200 for kidney disorders and IC 100's multi-targeted approach to inflammation. Our collection spans essential updates like trial results, research partnerships, and peer-reviewed study publications, ensuring you stay informed about breakthroughs in high-need therapeutic areas.
This resource eliminates the need to track multiple sources by aggregating essential updates about ZyVersa's evidence-based drug development. Discover how the company addresses conditions like focal segmental glomerulosclerosis and metabolic complications through its unique 'pipeline within a product' strategy.
Bookmark this page for efficient tracking of ZVSA's progress in transforming treatment paradigms. Check regularly for new developments directly impacting the company's position in the biopharmaceutical sector.
ZyVersa Therapeutics (ZVSA) announces publication of research demonstrating that its Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in a Retinopathy of Prematurity (ROP) animal model. The study, published in Angiogenesis, showed that IC 100 suppressed retinal microglia activation, attenuated inflammation, abnormal vascularization, and retinal thinning. Key findings include:
- IC 100 decreased expression of inflammasome-related molecules and inflammatory cytokines
- It reduced ASC speck formation and microglial activation
- Structural and functional improvements correlated with corrections of hyperoxia-modulated gene pathways
This research supports IC 100's potential in treating ROP, a leading cause of childhood blindness worldwide, and adds to its promising indications including early Alzheimer's disease, multiple sclerosis, and acute respiratory distress syndrome.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced that its CEO, Stephen C. Glover, will speak at the H.C. Wainwright 3rd Annual Kidney Conference on July 15, 2024. During his presentation, Glover will discuss the unique mechanism of Cholesterol Efflux Mediator™ VAR 200, which is in Phase 2a development for treating kidney diseases. The conference, held virtually, will also allow participants to schedule one-on-one meetings with Glover. With over 37 million Americans suffering from chronic kidney disease, ZyVersa is advancing its pipeline to address this significant unmet medical need.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced its Q1-2024 financial results and provided a business update. Net losses were $2.8 million, a 20.2% improvement from Q1-2023. The company has $2.0 million in cash, sufficient for month-to-month operations but will need additional financing. Key developments include the initiation of a Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in diabetic kidney disease and upcoming GLP toxicology studies for Inflammasome ASC Inhibitor IC 100. Other milestones include preclinical data readouts and collaborations for IC 100, focusing on atherosclerosis and obesity-related conditions. ZyVersa raised $2.7 million through warrant exercises.
ZyVersa Therapeutics announced that CEO Stephen C. Glover will participate in the 2024 BIO International Convention in San Diego from June 3-6, 2024. ZyVersa is developing treatments for renal and inflammatory diseases using two proprietary technologies: the Cholesterol Efflux Mediator™ VAR 200 and the Inflammasome ASC Inhibitor IC 100. The company plans to start a Phase 2a clinical trial for VAR 200 in diabetic kidney disease in the first half of 2024 and is conducting preclinical studies for expanding IC 100's indications to atherosclerosis, obesity, and Parkinson’s disease. An IND filing for IC 100 is expected by year-end, with Phase 1 trials starting in Q1-2025. Glover will be available for one-on-one meetings to discuss these developments.
ZyVersa Therapeutics, Inc. announces a publication highlighting the role of inflammasome-mediated inflammation in Alzheimer's Disease (AD) and its impact on heart health. The company is developing Inflammasome ASC Inhibitor IC 100 to target multiple inflammasomes and reduce inflammation. The research indicates a potential therapeutic target for cardiac comorbidities in AD and beyond.
FAQ
What is the current stock price of ZyVersa Therapeutics (ZVSA)?
What is the market cap of ZyVersa Therapeutics (ZVSA)?
